Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Absence of allelic imbalance involving EMSY, CAPN5, and PAK1 genes in papillary thyroid carcinoma.

Hidalgo M, Saez ME, Martinez-Tello FJ, Moron FJ, Ferrero-Herrero E, Labalde-Martinez M, Rigopoulou D, Ballestin-Carcavilla C, Ruiz A, Royo JL, Ramirez-Lorca R.

J Endocrinol Invest. 2008 Jul;31(7):618-23.

PMID:
18787380
2.

Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.

Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, Pollack J, Huntsman D.

Gynecol Oncol. 2006 Feb;100(2):264-70. Epub 2005 Oct 19.

PMID:
16236351
3.

Amplification of 11q13 in ovarian carcinoma.

Brown LA, Kalloger SE, Miller MA, Shih IeM, McKinney SE, Santos JL, Swenerton K, Spellman PT, Gray J, Gilks CB, Huntsman DG.

Genes Chromosomes Cancer. 2008 Jun;47(6):481-9. doi: 10.1002/gcc.20549.

PMID:
18314909
4.

Exploring allelic imbalance within paraffin-embedded tumor biopsies using pyrosequencing technology.

Pascual MH, Royo JL, Martínez-Tello FJ, Crespo C, Salinas A, Herrero EF, Lopez-García M, Real LM, Ruiz A, Ramirez-Lorca R.

Clin Chem Lab Med. 2006;44(9):1076-81.

PMID:
16958598
5.

Common variation in EMSY and risk of breast and ovarian cancer: a case-control study using HapMap tagging SNPs.

Benusiglio PR, Lesueur F, Luccarini C, McIntosh J, Luben RN, Smith P, Dunning A, Easton DF, Ponder BA, Pharoah PD.

BMC Cancer. 2005 Jul 19;5:81.

6.

The EMSY Gene Collaborates with CCND1 in Non-Small Cell Lung Carcinogenesis.

Baykara O, Dalay N, Bakir B, Bulut P, Kaynak K, Buyru N.

Int J Med Sci. 2017 Jun 23;14(7):675-679. doi: 10.7150/ijms.19355. eCollection 2017.

7.

Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma.

Lesueur F, Corbex M, McKay JD, Lima J, Soares P, Griseri P, Burgess J, Ceccherini I, Landolfi S, Papotti M, Amorim A, Goldgar DE, Romeo G.

J Med Genet. 2002 Apr;39(4):260-5.

8.

Functional characterization of EMSY gene amplification in human cancers.

Wilkerson PM, Dedes KJ, Wetterskog D, Mackay A, Lambros MB, Mansour M, Frankum J, Lord CJ, Natrajan R, Ashworth A, Reis-Filho JS.

J Pathol. 2011 Sep;225(1):29-42. doi: 10.1002/path.2944. Epub 2011 Jul 7.

PMID:
21735447
9.

Functional evaluation of TERT-CLPTM1L genetic variants associated with susceptibility of papillary thyroid carcinoma.

Ge M, Shi M, An C, Yang W, Nie X, Zhang J, Lv Z, Li J, Zhou L, Du Z, Yang M.

Sci Rep. 2016 May 17;6:26037. doi: 10.1038/srep26037.

10.

A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24.

He H, Nagy R, Liyanarachchi S, Jiao H, Li W, Suster S, Kere J, de la Chapelle A.

Cancer Res. 2009 Jan 15;69(2):625-31. doi: 10.1158/0008-5472.CAN-08-1071.

11.

Association between single nucleotide polymorphisms of upstream transcription factor 1 (USF1) and susceptibility to papillary thyroid cancer.

Yuan Q, Bu Q, Li G, Zhang J, Cui T, Zhu R, Mu D.

Clin Endocrinol (Oxf). 2016 Apr;84(4):564-70. doi: 10.1111/cen.12832. Epub 2015 Aug 14.

PMID:
26052935
12.

Age at diagnosis and gender modify the risk of 9q22 and 14q13 polymorphisms for papillary thyroid carcinoma.

Kula D, Kalemba M, Puch Z, Polańska J, Świerniak M, Rusinek D, Żebracka-Gala J, Kowalska M, Handkiewicz-Junak D, Kowal M, Tyszkiewicz T, Piasna E, Czarniecka A, Pawlaczek A, Krajewska J, Szpak-Ulczok S, Jarząb B.

Endokrynol Pol. 2017;68(3):283-289. doi: 10.5603/EP.2017.0021.

13.

Gain of 1q and loss of 9q21.3-q32 are associated with a less favorable prognosis in papillary thyroid carcinoma.

Kjellman P, Lagercrantz S, Höög A, Wallin G, Larsson C, Zedenius J.

Genes Chromosomes Cancer. 2001 Sep;32(1):43-9. Review.

PMID:
11477660
14.

Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome.

Rodriguez C, Hughes-Davies L, Vallès H, Orsetti B, Cuny M, Ursule L, Kouzarides T, Theillet C.

Clin Cancer Res. 2004 Sep 1;10(17):5785-91.

15.

Single nucleotide polymorphisms of ataxia telangiectasia mutated and the risk of papillary thyroid carcinoma.

Song CM, Kwon TK, Park BL, Ji YB, Tae K.

Environ Mol Mutagen. 2015 Jan;56(1):70-6. doi: 10.1002/em.21898. Epub 2014 Sep 4.

PMID:
25196645
16.

Contribution of ATM and FOXE1 (TTF2) to risk of papillary thyroid carcinoma in Belarusian children exposed to radiation.

Damiola F, Byrnes G, Moissonnier M, Pertesi M, Deltour I, Fillon A, Le Calvez-Kelm F, Tenet V, McKay-Chopin S, McKay JD, Malakhova I, Masyakin V, Cardis E, Lesueur F, Kesminiene A.

Int J Cancer. 2014 Apr 1;134(7):1659-68. doi: 10.1002/ijc.28483. Epub 2013 Oct 15.

17.

Correlation between polymorphisms of BRAF gene and papillary thyroid carcinoma.

Jiang R, Zhao C, Xu H, Zhao M, Sun X, Wang X, Song W.

Clin Endocrinol (Oxf). 2016 Mar;84(3):431-7. doi: 10.1111/cen.12804. Epub 2015 Jun 1.

PMID:
25916409
18.

Association of FOXE1 polyalanine repeat region with papillary thyroid cancer.

Bullock M, Duncan EL, O'Neill C, Tacon L, Sywak M, Sidhu S, Delbridge L, Learoyd D, Robinson BG, Ludgate M, Clifton-Bligh RJ.

J Clin Endocrinol Metab. 2012 Sep;97(9):E1814-9. doi: 10.1210/jc.2012-1456. Epub 2012 Jun 26.

PMID:
22736773
19.

Missense polymorphisms in XIAP-associated factor-1 (XAF1) and risk of papillary thyroid cancer: correlation with clinicopathological features.

Kim SK, Park HJ, Seok H, Jeon HS, Kim JW, Chung JH, Kwon KH, Woo SH, Lee BW, Baik HH.

Anticancer Res. 2013 May;33(5):2205-10.

PMID:
23645777
20.

Association of HLA DQ4-DR8 haplotype with papillary thyroid carcinomas.

Porto T, Coelho I, Boavida J, Pereira C, Nunes JM, Mendonça D, Martins B, Sobrinho LG, Leite V.

Clin Endocrinol (Oxf). 2006 Feb;64(2):179-83.

PMID:
16430717

Supplemental Content

Support Center